Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.31 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.31 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18169351 | 1.00 | FFAR3 (0.35) | FFAR3TSHRKDM4EALDH1A1GRIK1 | |
| SCHEMBL23709589 | 0.85 | TDP1 (0.33) | FFAR3TSHRALDH1A1 | |
| SCHEMBL2747280 | 0.82 | HDAC3 (0.39) | FFAR3TSHRKDM4EALDH1A1GRIK1 | |
| SCHEMBL1245379 | 0.81 | ALDH1A1 (0.37) | TSHRKDM4EALDH1A1 | |
| SCHEMBL15103541 | 0.81 | — | — | |
| SCHEMBL4375015 | 0.81 | ALDH1A1 (0.35) | FFAR3TSHRKDM4EALDH1A1GRIK1 | |
| SCHEMBL4375017 | 0.81 | ALDH1A1 (0.35) | FFAR3TSHRKDM4EALDH1A1GRIK1 | |
| SCHEMBL2431228 | 0.80 | NPSR1 (0.41) | TSHRALDH1A1 | |
| SCHEMBL2308752 | 0.79 | TSHR (0.33) | FFAR3TSHRKDM4EALDH1A1GRIK1 | |
| SCHEMBL4273874 | 0.79 | TSHR (0.33) | FFAR3TSHRKDM4EALDH1A1GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150004224-A1 | DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM | OMTHERA PHRMACEUTICALS INC (US) | 2015-01-01 | — | — | US | claimed |
| EP-2800563-A1 | DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM | Omthera Pharmaceuticals Inc. (US) | 2014-11-12 | — | — | EP | claimed |
| US-20130177643-A1 | DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM | CHRYSALIS PHARMA AG (CH) | 2013-07-11 | — | — | US | claimed |
| WO-2013103902-A1 | DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM | OMTHERA PHARMACEUTICALS, INC. (US) | 2013-07-11 | — | — | WO | claimed |
| EP-3348262-A1 | METHODS FOR MAKING DPA-ENRICHED COMPOSITIONS OF OMEGA-3 POLYUNSATURATED FATTY ACIDS IN FREE ACID FORM | Omthera Pharmaceuticals Inc. (US) | 2018-07-18 | — | — | EP | disclosed |
| US-20160347908-A1 | PROCESS FOR PRODUCING NYLON-6,6 | BASF SE (DE) | 2016-12-01 | — | — | US | disclosed |
| US-20160326092-A1 | METHOD FOR PRODUCING HEXAMETHYLENEDIAMINE | BASF SE (DE) | 2016-11-10 | — | — | US | disclosed |
| US-20160311739-A1 | METHOD FOR PREPARING 1,6-HEXANEDIOL | BASF SE (DE) | 2016-10-27 | — | — | US | disclosed |
| EP-1758574-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACID AND AT LEAST ONE OF AN IMMUNOSUPPRESSIVE AGENT OR AN ANTINEOPLASTIC AGENT | TILLOTTS PHARMA AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| EP-1758573-A1 | A PHARMACEUTICAL COMPOSITION AND ITS USE | TILLOTTS PHARMA AG (CH) | 2007-03-07 | — | — | EP | disclosed |
| WO-2005123060-A1 | A PHARMACEUTICAL COMPOSITION AND ITS USE | TILLOTTS PHARMA AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| WO-2005123061-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING POLYUNSATURATED FATTY ACID AND AT LEAST ONE OF AN IMMUNOSUPPRESSIVE AGENT OR AN ANTINEOPLASTIC AGENT | TILLOTTS PHARMA AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-5449703-A | Acrylic monomer and free radical catalysts for dentures | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-09-12 | — | — | US | disclosed |
| US-5318999-A | Denture base, liner or restorative, controlled curing | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1994-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160326092-A1 | METHOD FOR PRODUCING HEXAMETHYLENEDIAMINE | MUC1, HEXD, HEXA | FFAR3 1798/4885TSHR 3756/4885KDM4E 3657/4885 |
| US-20160311739-A1 | METHOD FOR PREPARING 1,6-HEXANEDIOL | MUC1, HEXD, HPD | FFAR3 1885/4885TSHR 4434/4885KDM4E 4858/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.